Remission maintenance treatment options in chronic lymphocytic leukemia.

Alexander Egle; Lisa Pleyer; Thomas Melchardt; Tanja Hartmann; Richard Greil

doi:10.1016/j.ctrv.2018.08.003

Remission maintenance treatment options in chronic lymphocytic leukemia.

Alexander Egle (Erstautor/-in), Lisa Pleyer (Co-Autor/-in), Thomas Melchardt (Co-Autor/-in), Tanja Hartmann (Co-Autor/-in), Richard Greil^* (Letztautor/-in)

^*Korrespondierende/r Autor/-in für diese Arbeit

Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Begutachtung

2 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	56-66
Fachzeitschrift	CANCER TREATMENT REVIEWS
Jahrgang	70
DOIs	https://doi.org/10.1016/j.ctrv.2018.08.003
Publikationsstatus	Veröffentlicht - 2018

Zugriff auf Dokument

10.1016/j.ctrv.2018.08.003

Dieses zitieren

Egle, A., Pleyer, L., Melchardt, T., Hartmann, T., & Greil, R. (2018). Remission maintenance treatment options in chronic lymphocytic leukemia. CANCER TREATMENT REVIEWS , 70, 56-66. https://doi.org/10.1016/j.ctrv.2018.08.003

Egle, Alexander ; Pleyer, Lisa ; Melchardt, Thomas et al. / Remission maintenance treatment options in chronic lymphocytic leukemia. in: CANCER TREATMENT REVIEWS 2018 ; Jahrgang 70. S. 56-66.

@article{b07693fe7b85477f8a8e221ce7c1057a,

title = "Remission maintenance treatment options in chronic lymphocytic leukemia.",

keywords = "MINIMAL RESIDUAL DISEASE, PROGRESSION-FREE SURVIVAL, PHASE-II TRIAL, FLUDARABINE-CYCLOPHOSPHAMIDE-RITUXIMAB, MULTIPARAMETER FLOW-CYTOMETRY, TERM-FOLLOW-UP, CLONAL EVOLUTION, OPEN-LABEL, ALEMTUZUMAB CONSOLIDATION, 1ST-LINE TREATMENT",

author = "Alexander Egle and Lisa Pleyer and Thomas Melchardt and Tanja Hartmann and Richard Greil",

note = "Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Austria; Salzburg Cancer Research Institute and Cancer Cluster Salzburg, Austria",

year = "2018",

doi = "10.1016/j.ctrv.2018.08.003",

language = "English",

volume = "70",

pages = "56--66",

journal = "CANCER TREATMENT REVIEWS ",

issn = "0305-7372",

}

Egle, A , Pleyer, L , Melchardt, T, Hartmann, T & Greil, R 2018, 'Remission maintenance treatment options in chronic lymphocytic leukemia.', CANCER TREATMENT REVIEWS , Jg. 70, S. 56-66. https://doi.org/10.1016/j.ctrv.2018.08.003

Remission maintenance treatment options in chronic lymphocytic leukemia. / Egle, Alexander (Erstautor/-in); Pleyer, Lisa (Co-Autor/-in); Melchardt, Thomas (Co-Autor/-in) et al.
in: CANCER TREATMENT REVIEWS , Jahrgang 70, 2018, S. 56-66.

Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Begutachtung

TY - JOUR

T1 - Remission maintenance treatment options in chronic lymphocytic leukemia.

AU - Egle, Alexander

AU - Pleyer, Lisa

AU - Melchardt, Thomas

AU - Hartmann, Tanja

AU - Greil, Richard

N1 - Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Austria; Salzburg Cancer Research Institute and Cancer Cluster Salzburg, Austria

PY - 2018

Y1 - 2018

KW - MINIMAL RESIDUAL DISEASE

KW - PROGRESSION-FREE SURVIVAL

KW - PHASE-II TRIAL

KW - FLUDARABINE-CYCLOPHOSPHAMIDE-RITUXIMAB

KW - MULTIPARAMETER FLOW-CYTOMETRY

KW - TERM-FOLLOW-UP

KW - CLONAL EVOLUTION

KW - OPEN-LABEL

KW - ALEMTUZUMAB CONSOLIDATION

KW - 1ST-LINE TREATMENT

U2 - 10.1016/j.ctrv.2018.08.003

DO - 10.1016/j.ctrv.2018.08.003

M3 - Review article

C2 - 30121491

SN - 0305-7372

VL - 70

SP - 56

EP - 66

JO - CANCER TREATMENT REVIEWS

JF - CANCER TREATMENT REVIEWS

ER -

Egle A , Pleyer L , Melchardt T, Hartmann T, Greil R. Remission maintenance treatment options in chronic lymphocytic leukemia. CANCER TREATMENT REVIEWS . 2018;70:56-66. doi: 10.1016/j.ctrv.2018.08.003